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Background: 
Vincristine-induced peripheral neuropathy is a major dose limiting side effect and thus effective therapeutic 
strategy is required. In this study, we investigated the antinociceptive effect of memantine and morphine on 
a vincristine-induced peripheral neuropathy model in rats. 
Methods: 
Male Sprague-Dawley rats weighing 220−240 g were used in all experiments. Rats subsequently received daily 
intraperitoneal injections of either vincristine sulfate (0.1 ml/kg/day) or saline (0.1 ml/kg/day) over 12 days, 
immediately following behavioral testing. For assessment of mechanical allodynia, mechanical stimuli using von 
Frey filament was applied to the paw to measure withdrawal threshold. The effects of N-methyl-D-aspartate 
receptors antagonist (memantine; 2.5, 5, 10 mg/kg intraperitoneal), opioid agonist (morphine; 2.5, 5, 10 mg/kg 
intraperitoneal) and vehicle (saline) on vicristine-induced neuropathy were evaluated. 
Results: 
Mechanical allodynia developed over the course of ten daily injections of vincristine relative to groups 
receiving saline at the same time. Morphine abolished the reduction in paw withdrawal threshold compared 
to vehicle and produced dose-responsiveness. Only the highest dose of memantine (10 mg/kg) was able to 
increase paw withdrawal threshold compared to vehicle. 
Conclusions: 
Systemic morphine and memantine have an antinociceptive effect on the vincristine-induced peripheral 
neuropathy model in rats. These results suggest morphine and memantine may be an alternative approach 
for the treatment of vincristine-induced peripheral neuropathic pain. (Korean  J  Pain  2010;  23:  179-185)
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INTRODUCTION
    Painful peripheral neuropathy is one of the main side 
effects  induced  by  diverse  classes  of  chemotherapeutic 
agents, including vincristine [1,2]. Vincristine is one of the 
most common chemotherapeutic drugs used to treat a wide 
variety of malignancies, including leukemia and lymphoma, 
and prevents tumor cell replication through alteration of 
cytoskeletal  structure  and  disorientation  of  microtubules 
[3,4]. However, vincristine may also induce painful periph-
eral neuropathy. The chief clinical manifestation of vin-
cristine-induced  peripheral  neuropathy  is  disturbance  in 
b o t h  s e n s o r y  a n d  m o t o r  f u n c t i o n  [ 5 , 6 ] .  S e n s o r y  d i s -
turbances range from mild tingling to spontaneous painful 
burning paresthesia and hypersensitivity to painful stimuli 
[7].  Vincristine-induced  painful  peripheral  neuropathy  is 
t h e  m a j o r  d o s e - l i m i t i n g  s i d e  e f f e c t  a n d  r e q u i r e s  d i s -
continuation of treatment, greatly impacting on the sur-
vival of cancer patients [8]. Moreover, the resulting symp-
toms, which frequently include moderate to severe pain, 
can often be disabling and cause significant loss of func-
tional abilities and decreased quality of life [9]. 
    Although  it  has  been  hypothesized  that  vincris-
tine-induced neuropathic pain is due to neuronal toxicity 
and/or neurological disorder [10,11], the exact mechanism 
r e s p o n s i b l e  i s  s t i l l  u n k n o w n .  R e c e n t l y ,  W e n g  e t  a l .  [ 1 2 ]  
suggested a state of central sensitization develops in spinal 
wide dynamic range (WDR) neurons with repeated vincris-
tine treatment that contributes to the neuropathic pain. 
    Unfortunately,  neither  prophylactic  strategies  nor 
symptomatic treatments of this chemotherapy-induced peri-
pheral neuropathy (CIPN) have proven useful yet. Aspirin, 
ibuprofen and celebrex are commonly prescribed to patients 
to treat CIPN but show limited efficacy [13]. Furthermore, 
gabapentin,  lamotrigine,  nortriptyline  and  amitriptyline 
studies were disappointing in treating CIPN [14], and there 
have been no trials of opioids in patients with CIPN. 
    Data concerning the effectiveness of opioids on neu-
ropathic pain have been controversial [15]. However, animal 
models [16] and controlled patient trials [17] suggest that 
μ-opioid  receptor  agonists  are  effective  at  attenuating 
neuropathic pain. Recently, opioid analgesics were recom-
mended as second-line treatment that can be considered 
for first-line use in certain clinical circumstances [18]. 
    Much evidence suggests that N-methyl-D-aspartate 
(NMDA) receptors play an important role in the generation 
of central sensitization, and in the development and main-
t e n a n c e  o f c hr o n i c  p a in  [19 ,2 0 ].  O n t h is  ba s is ,  a d m in-
istration of NMDA receptor antagonists could be useful for 
the  treatment  of  chronic  pain  [21,22].  Memantine,  an 
amantadine derivative, is a noncompetitive NMDA antago-
nist that is better tolerated in patients because it is an 
open channel blocker with a fast off-rate compared with 
ketamine [23]. In the spinal nerve ligation model, mem-
antine has been shown to be more effective in reversing 
allodynia and has produced the least motor impairment, as 
com pared to MK-801 or k etamine [24]. The absence of 
confirmed treatments for CIPN makes the identification of 
effective alternative analgesics a necessity. 
    In this study, we investigated the antinociceptive ef-
fect of morphine and memantine on the vincristine- 
induced peripheral neuropathy model in rats. 
MATERIALS  AND  METHODS
    All experiments followed the Guidelines on Ethical 
Standards  for  Investigation  of  Experimental  Pain  in 
Animals [25]. Bedding containing metabolized vincristine 
was treated as biohazardous waste and disposed of, ac-
cording to the appropriate institutional guidelines. 
    Male Sprague-Dawley rats weighing 220-240 g were 
used in all experiments. Animals were acclimated to the 
laboratory environment for 5-7 days before being used in 
the study. While in the home cage environment, animals 
were allowed free access to a standard rat diet and tap 
water. Room temperature was maintained at 20-23
oC with 
12:12 h ligh t/dark cy cle. Spon taneous beha vior w as ob-
served in cages before starting experimental procedures, 
and rats showing aggressiveness or alterations in motility 
were  discarded.  An  observer  blinded  to  drug  treatment 
conducted all behavioral assays.
    The vincristine-induced peripheral neuropathy model 
induced by intraperitoneal (i.p.) injection was used in this 
experiment.  Briefly,  baseline  responses  to  mechanical 
stimulation of the hindpaw were established on day zero 
(baseline). Rats subsequently received daily i.p. injections 
of either vincristine sulfate (0.1 ml/kg/day) or saline (0.1 
ml/kg/day) over 12 days, immediately following behavioral 
testing. The treatment paradigm consisted of five daily in-
jections, followed by a 2-day interval where no injections 
were administered, followed by five subsequent daily in-
jections, as described previously [12]. In all studies, the in-BY Park, et al / Memantine and Morphine on CIPN 181
Fig. 1. Time course of hind paw withdrawal response to von
Frey filaments after vincristine treatment. Data are presented
as withdrawal threshold. Each line represents mean ± SEM
of 8 rats. BL: baseline withdrawal threshold measured 
before vincristine treatment. Significant differences between
saline (control) and vincristine treatment are indicated.
*P  ＜ 0.05, 
†P ＜ 0.01.
vestigator was blinded to drug treatments. 
    The following drugs were used in this study: vincris-
tine sulfate (Tocris Cookson Ltd., Bristol, Avon, UK), mem-
antine hydrochloride (Tocris), and morphine sulfate (Sigma 
Aldrich Co., St. Louis, MO, USA). All drugs were dissolved 
i n  0 . 9 %  s a l i n e  f o r  s y s t e m i c  a d m i n i s t r a t i o n  a n d  a d -
ministered in a volume of 0.1 ml/kg body weight. The dose 
of morphine and memantine were decided based on pre-
vious studies utilizing the neuropathic pain model [16,24]. 
    Mechanical allodynia was assessed using von Frey fil-
aments (Stoelting, Wood Dale, IL, USA), as described pre-
viously, to determine the 50% probability paw withdrawal 
threshold  (PWT)  [26].  Rats  were  placed  in  a  separate 
transparent Plexi-glass chamber with a wire mesh floor 
underneath and acclimated to the test chambers for 30 
m i n .  T h e  P W T  w a s  m e a s u r e d  u s i n g  v o n  F r e y  f i l a m e n t s 
ranging from 0.4 to 15 g with a logarithmic increment. The 
f i l a m e n t  w a s  a p p l i e d  t o  t h e  p l a n t a r  h i n d p a w n ,  a n d  t h e 
force of each application was made optimal and consistent 
by having the filament bent to the same extent and main-
tained for 6 seconds. Withdrawal of paw or licking during 
the application was considered as a positive response. If 
the rat responded positively, the stiffer filament was used 
for the next trial; when no withdrawal or licking was ob-
served, the less stiff one was used. The cut-off value was 
determined as 15 g, where the PWT for the rat was 15 g 
if the rat did not show any withdrawal or licking response 
to the application of a 15 g von Frey filament. Rats that 
demonstrated no allodynia (less than 4 g) were not ex-
cluded from this study. 
    On the day of experimen ts (on da y 12), rats w ere allo-
cated to receive one of the experimental drugs. The vehicle 
study was done using i.p. saline. Animals were tested only 
once, and all experiments were carried out by an observer 
blind to drug treatments.
    The eff ects of NMD A receptor antagonist (memantine; 
2.5, 5, 10 mg/kg i.p.) and opioid agonist (morphine; 2.5, 
5, 10 mg/kg i.p.) were investigated in a vincristine-induced 
peripheral neuropathic pain state. The mechanical thresh-
o l d  m e a s u r e d  b e f o r e  v i n c r i s t i n e  a d m i n i s t r a t i o n  w a s  r e-
garded  as  the  baseline  threshold,  while  the  withdrawal 
threshold  measured  immediately  before  i.p.  delivery  of 
drugs was regarded as control. The withdrawal threshold 
was determined at 15, 30, 45, 60, and 90 min after i.p. 
administration of experimental drugs. 
    Data were expressed as mean ± SEM. Time response 
data  were  presented  as  the  withdrawal  threshold  in  g. 
Dose-response  data  were  presented  as  the  percent  of 
maximum  possible  effect  (%MPE).  Withdrawal  threshold 
d a t a  f r o m  v o n  F r e y  f i l a m e n t  t e s t i n g  w e r e  c o n v e r t e d  t o 
% M P E ,  a c c o r d i n g  t o  t h e  f o r m u l a :  % M P E  =  [ ( p o s t d r u g  
t h r e s h o l d  -  p o s t - i n j u r e d  b a s e l i n e  t h r e s h o l d )  /  ( c u t o f f  
threshold - post-injured baseline threshold)] × 100. In 
behavioral  experiments,  dose-response  data  were  ana-
l y z e d  b y  o n e - w a y  a n a l y s i s  o f  v a r i a n c e  ( A N O V A ) ,  w i t h  
Scheffe for post hoc analysis. Differences in withdrawal 
threshold between multiple groups were analyzed by re-
peated measures ANOVA. P values of ＜ 0.05 were consid-
ered statistically significant. 
RESULTS
1. Effect  of  chronic  administration  of  vincristine  on 
nociceptive thresholds to mechanical stimuli
    None of the vincristine-treated rats showed any mo-
tor dysfunction, guarding or obvious change in motor ac-
tivity when observed in their home cages. All rats remained 
alert during the experiment. No difference between data 
recorded from the left or right hindpaws was found; there-
fore, withdrawal thresholds were presented as the mean 
of duplicate measurements, averaged across paws. 
    Vincristine significantly reduced the mechanical with-182 Korean J Pain Vol. 23, No. 3, 2010
Fig. 3. Effects of intraperitoneal morphine for hindpaw withdrawal response to von Frey filaments after vincristine treatment.
Data are presented as withdrawal threshold or percent of maximal possible effect (%MPE). Each line represents mean ±
SEM of 6−7 rats. BL: baseline withdrawal threshold measured before vincristine treatment. Control data were measured 
immediately before intraperitoneal delivery of drug. Intraperitoneal morphine produced a dose-dependent increase in 
withdrawal threshold. Compared with vehicle (saline). *P ＜ 0.05, 
†P  ＜ 0.01.
Fig. 2. Effects of intraperitoneal memantine for hindpaw withdrawal response to von Frey filaments after vincristine treatment.
Data are presented as withdrawal threshold or percent of maximal possible effect (%MPE). Each line represents mean ±
SEM of 6−7 rats. BL: baseline withdrawal threshold measured before vincristine treatment. Control data were measured 
immediately before intraperitoneal delivery of drug. Compared with vehicle (saline). *P  ＜ 0.01.
drawal  threshold  when  compared  to  the  vehicle-treated 
group (Fig. 1). Mechanical withdrawal threshold was sig-
nificantly reduced after vincristine treatment from Day 3 
to Day 12 when compared to base line (Fig. 1). 
2. Eff ect of i.p. administration of mem an tine on m ec-
hanical withdrawal thresholds
    Administration of memantine (2.5, 5 and 10 mg/kg) at 
Day 12 also abolished the reduction in mechanical with-
drawal thresholds only at the highest dose, returning PWT 
to control values (Fig. 2). The lower dose of memantine 
(2.5, 5 mg/kg) produced no significant reversal of tactile 
allodynia, while the highest dose of memantine (10 mg/kg) 
effectively  increased  mechanical  withdrawal  threshold 
compared to vehicle.
3. Effect of i.p. administration of morphine on mechanical 
withdrawal thresholds
    After repeated i.p. administration of vincristine, ad-
ministration of morphine (2.5, 5 and 10 mg/kg) at Day 12 
abolished the reduction in mechanical withdrawal thresh-
olds in a dose dependent manner (Fig. 3). The effect of 
2.5 mg/kg of morphine was not significantly different from 
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tactile  threshold  to  mechanical  stimulation.  The  higher 
doses of morphine (5 and 10 mg/kg) increased withdrawal 
threshold to tactile stimulation compared to vehicle. 
DISCUSSION
    In the present study, systemic administration of mor-
phine  produced  significant  anti-allodynic  effects  and 
dose-responsiveness. Lower doses of memantine (2.5, 5 
mg/kg) produced no significant reversal of tactile allodynia, 
however the highest dose (10 mg/kg) effectively increased 
mechanical withdrawal threshold. 
    CIPN is a common and major dose limiting side eff ect 
o f  m a n y  c h e m o t h e r a p e u t i c  a g e n t s .  T h e  m o s t  f r e q u e n t l y 
reported agents include many older commonly used che-
motherapeutic agents, such as platinum drugs, taxanes, 
epothilones  and  vinca  alkaloids,  but  also  newer  agents 
such as bortezomib and lenolidamide [9,14]. The choice of 
chemotherapeutic agent, dosing schedule, type of cancer 
and presence of concomitant medical problems all affect 
the incidence and severity of chemotherapy-induced neu-
ropathy  [27,28].  The  exact  mechanism  by  which  these 
agents cause CIPN is still unknown. Moreover, mechanisms 
are likely to be different and specific for each agent and, 
therefore, treatments may need to be agent-specific [14].
    Experimental models of vincristine-induced peripheral 
neuropathic pain have been established in rodents using 
different systemic dosing schedules of vincristine. Present 
data were obtained using the vincristine model in rats [12]. 
In this model, it has been reported that in contrast to the 
change in response to mechanical stimulation, there was 
no significant change in latency of hind paw withdrawal 
responses to radiant heat stimuli after vincristine treat-
ment [12,29]. 
    In this study, we examined if two common analgesic 
drugs with clinical use would have an antinociceptive effect 
o n  n e u r o p a t h i c  p a i n  i n d u c e d  b y  v i n c r i s t i n e .  T h e s e  a n-
algesic drugs were selected because morphine is the refer-
ence opioid compound, while memantine is an NMDA an-
tagonist used in several pain states. 
    NMD A receptors antagonist, memantine, has been 
used to treat Parkinson's disease, spasticity, convulsions, 
vascular dementia, and Alzheimer's disease with an ex-
tremely low incidence of side effects in human clinical trials 
[30,31]. It has also been reported that memantine is effec-
tive in the treatment of complex regional pain syndrome 
[32] and phantom limb pain [33]. In the present study, low-
er doses of memantine (2.5, 5 mg/kg) produced no sig-
nifican t re v ersal of tactile allodynia, howe v er the higher 
dose of memantine (10 mg/kg) effectively increased me-
chanical withdrawal threshold. This result is in agreement 
w i t h  t h e  e f f e c t  o f  m e m a n t i n e  i n  c h r o n i c  p a i n  m o d e l s  
[ 3 4 - 3 6 ] .  M e d v e d e v  e t  a l .  [ 3 6 ]  r e p o r t e d  t h a t  m e m a n t i n e 
caused a dose-dependent reduction in the intensity of for-
m a lin-ind u ced gr oom ing be ha vi or an d a 10 mg/kg d ose 
attenuated  tactile  allodynia  induced  by  sciatic  nerve 
ligation. This result may reflect a contribution of the NMDA 
receptor system in vincristine-induced peripheral neuro-
p a t h y .  I t  i s  p o s s i b l e  t h a t  u n d e r  t h e  p r e s e n t  c o n d i t i o n s  
higher doses of memantine would produce stronger effects. 
However, higher doses were not tested because of motor 
side effects (ataxia, incoordination and restlessness) that 
preclude efficient determination of tactile thresholds [36]. 
    Recently, animal models and controlled patient trials 
suggest that μ-opioid receptor agonists are effective at 
attenuating neuropathic pain [16,17]. In this study, sys-
temic morphine significantly increased the PWT compared 
to vehicle and produced dose-responsiveness. The effect 
of 2.5 mg/kg of morphine on tactile threshold to mechan-
ical stimulation was not significantly different from control 
values. However, at doses of 5 and 10 mg/kg, morphine 
increased the withdrawal threshold to tactile stimulation 
w h e n  c o m p a r e d  w i t h  v a l u e s  o b t a i n e d  b e f o r e  m o r p h i n e  
treatment. Similar results have been published with other 
models of neuropathic pain [37,38]. Furthermore, a pre-
vious  study  demonstrated  that  morphine  (8  mg/kg  i.p.) 
suppressed vincristine-evoked mechanical allodynia rela-
tive to treatment with either vehicle or a lower dose (2.5 
mg/kg i.p.) of morphine [29]. In contrast, another study 
[39] found opioid agonists, such as morphine (5 mg/kg, i.p.) 
administered alone on 5 consecutive days, did not modify 
hyperalgesia in vincristine rats. This discrepancy could be 
due to differences in study protocol and rat strain. The 
beneficial effects of morphine warrant further investigation 
of its mechanism of action in vincristine-induced neuro-
pathic pain. 
    In conclusion, systemic memantine and morphine have 
an antiallodynic effect on the vincristine-induced periph-
eral neuropathy model in rats. Memantine and morphine 
may therefore offer an alternative approach to treatment 
of vincristine-induced neuropathic pain states. However, 
similar studies on various animal models are required to 184 Korean J Pain Vol. 23, No. 3, 2010
obtain a reliable oversight of the effect of theses drugs on 
vincristine-induced neuropathic pain in a clinical setting.
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